Diabetic cardiomyopathy is a chronic, progressive cardiovascular disease occurring in diabetic patients. It is a prevalent condition that often remains undiagnosed in its early stages due to the lack of symptoms and limited disease awareness. As the disease progresses, HF develops, and patients experience burdensome symptoms. No therapies have been approved to treat DbCM; treatment of patients focuses mainly on the optimal management of diabetes and its comorbid conditions with agents from the antidiabetic, antihypertensive, and lipid-modifying drug classes. The primary goal is to keep the underlying conditions in check to prevent the accelerated progression of DbCM. The DbCM pipeline is relatively bare; only one agent, Applied Therapeutics’ AT-001, has the potential to launch in the next 10 years. Nevertheless, SGLT-2 inhibitors, which are well-established antidiabetic drugs and gaining recognition for their beneficial role in treating HF, are likely to be widely used in this patient population. Considering the number of potential drug targets in DbCM, there is significant opportunity for drug developers to advance therapies with novel mechanisms of action.
- What are the key areas of unmet need and opportunity in the DbCM therapy market?
- What is the prevalence of DbCM in the United States?
- How are DbCM patients currently treated in the United States?
- What therapies are in development for DbCM?
- What are the key drivers and limiters of the DbCM therapy market?
Three KOL interviews in May /June 2020
KEY COMPANIES COVERED
Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly
- Diabetic Cardiomyopathy - Executive Insights - Executive Insights (US)
- 2020 Executive Insights Diabetic Cardiomyopathy
Author(s): Dominika Rudnicka-Noulin, PhD, MSc
Dominika Rudnicka-Noulin, PhD, MSc is a senior business insights analyst in the Cardiovascular, Metabolic and Renal division at Decision Resources Group, specializing in cardiovascular diseases, with expertise in heart failure and acute coronary syndrome.
Prior to joining DRG, Dominika held a position of an associate editor at Nature Communications, working across a variety of therapy areas. Dominika also worked for three years as a Postdoctoral Research Associate on a joint project between Imperial College London and MedImmune aimed at developing more potent antibody-based drugs. Dominika gained her PhD at the Institut Pasteur in Paris, France where her work was funded by the European Commission Marie Skłodowska-Curie Actions